pubmed· e01.org

PubMed · PMID 39398261

TRIP13: A promising cancer immunotherapy target.

PMID 39398261Journal Cancer innovationYear 2024Authors 5DOI 10.1002/cai2.147

  • Source PubMed
  • Journal Cancer innovation
  • Year 2024
  • Authors Shengnan Jing; Liya Zhao; Liwen Zhao; Yong-Jing Gao; Tianzhen He
  • Licence NLM/PubMed terms

Abstract

The tumor microenvironment (TME) facilitates tumor development through intricate intercellular signaling, thereby supporting tumor growth and suppressing the immune response. Thyroid hormone receptor interactor 13 (TRIP13), an AAA+ ATPase, modulates the conformation of client macromolecules, consequently influencing cellular signaling pathways. TRIP13 has been implicated in processes such as proliferation, invasion, migration, and metastasis during tumor progression. Recent studies have revealed that TRIP13 also plays a role in immune response suppression within the TME.

Thus, inhibiting these functions of TRIP13 could potentially enhance immune responses and improve the efficacy of immune checkpoint inhibition. This review summarizes the recent research progress of TRIP13 and discusses the potential of targeting TRIP13 to improve immune-based therapies for patients with cancer.

Record details

PMID39398261
DOI10.1002/cai2.147
JournalCancer innovation
Year2024
AuthorsShengnan Jing; Liya Zhao; Liwen Zhao; Yong-Jing Gao; Tianzhen He
MeSHnot stated

Source record

Open the PubMed record. This page reproduces the abstract and citation fields held in the local baseline; it does not rehost the article.

Source
PubMed / NLM
PMID
39398261
Rendered
2026-11-20
Completeness
Abstract and citation fields only; full text is not rehosted.